Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE: Neoadjuvant AC followed by Eribulin in HER2-negative Breast Cancer
NCT02215876Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2014
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Sep 2014; status: withdrawn.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02215876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215876.